This study conducted an indirect treatment comparison (ITC) of iptacopan, the first
oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion
targeting complement component 3, in patients with paroxysmal nocturnal hemoglobinuria
(...